Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • AbCellera, Pfizer deal

    AbCellera will use its high-throughput single cell antibody platform to discover function-modulating antibodies against multiple undisclosed membrane protein targets. The company will receive an undisclosed upfront …

    Published on 1/16/2017
  • Aduro, Merck deal

    Aduro and Merck partnered to conduct a Phase II trial to evaluate Aduro's CRS-207 in combination with Merck's cancer drug Keytruda pembrolizumab to treat gastric cancer. Aduro will run the clinical trial, which will …

    Published on 1/16/2017
  • Amgen, immatics deal

    Amgen and Immatics partnered to develop T cell engaging bispecific immunotherapies to treat cancer. Immatics will receive $30 million up front and is eligible for more than $500 million in milestones for each program, …

    Published on 1/16/2017
  • Anokion, Celgene deal

    Celgene's Celgene Switzerland LLC affiliate and Anokion partnered to use Anokion's immune tolerizing platform to develop therapies for autoimmune diseases. Anokion will receive $45 million up front, which includes an …

    Published on 1/16/2017
  • Ariad, Takeda deal

    Takeda will acquire cancer company Ariad for $24 per share in cash. Takeda said the deal gives Ariad an enterprise value of about $5.2 billion. The price is a 75% premium to Ariad's close of $13.74 on Jan. 6, the last …

    Published on 1/16/2017
  • Assembly, Allergan deal

    Assembly granted Allergan exclusive, worldwide rights to preclinical candidates ABI-M201, which is in development for ulcerative colitis; and ABI-M301, which is in development for Crohns disease. The deal also includes …

    Published on 1/16/2017
  • BioAtla, F1 Oncology and SunTerra deal

    BioAtla granted F1 Oncology exclusive, worldwide rights to IP for adoptive cellular therapy preparations and cancer treatments. The partners will aim to combine BioAtla's Conditionally Active Biologic (CAB) technology …

    Published on 1/16/2017
  • Biodesix, Bioyong deal

    Biodesix granted Bioyong rights to develop and commercialize in Taiwan and China, including Macau and Hong Kong, a version of Biodesixs VeriStrat that will run on Bioyong's mass spectrometry technology. The deal …

    Published on 1/16/2017
  • Clinigen, Cumberland deal

    Clinigen granted Cumberland exclusive rights to commercialize Totect dexrazoxane in the U.S. Cumberland plans to launch Totect in the U.S. later this year. The topoisomerase II (TOP2) inhibitor is approved in the U.S. …

    Published on 1/16/2017
  • Ferring, Intralytix deal

    Ferring and Intralytix partnered to develop and commercialize bacteriophage therapies targeting microbiome dysbiosis of the female reproductive tract, oral cavity and skin. The partners entered a separate deal in 2015 …

    Published on 1/16/2017
  • Futura, Stada Arzneimittel deal

    Futura granted Stadas Thornton & Ross Ltd. subsidiary rights to commercialize pain candidate TPR100 in the U.K. Thornton & Ross will submit a regulatory application next half. Futura will receive an undisclosed …

    Published on 1/16/2017
  • GeneCentric, Bristol-Myers Squibb deal

    Bristol-Myers Squibb and GeneCentric partnered to explore the feasibility of using GeneCentrics Cancer Subtype Platform (CSP) to identify translational biomarkers for cancer drug Opdivo nivolumab for use in clinical …

    Published on 1/16/2017
  • Genmab, Bristol-Myers, J&J deal

    The companies partnered to conduct Phase Ib/II trials of multiple myeloma (MM) drug Darzalex daratumumab in combination with Bristol-Myers' cancer drug Opdivo nivolumab in solid tumors and MM. BMS will fund the studies,…

    Published on 1/16/2017
  • Genmab, J&J deal

    Genmab will receive a $25 million milestone payment from Johnson & Johnsons Janssen Biotech Inc. unit under a 2012 deal granting the unit exclusive, worldwide rights to Darzalex daratumumab. Genmab said the …

    Published on 1/16/2017
  • Illumina, IBM deal

    IBM and Illumina will use the cloud-based platform IBM Watson for Genomics to compare variant genetic data produced by TruSight Tumor 170 to published medical literature. TruSight Tumor 170 is a research use only test …

    Published on 1/16/2017
  • Incyte, Merck deal

    The partners expanded their Phase III development plan for epacadostat (INCB024360) plus Keytruda pembrolizumab. This year, the companies plan to begin pivotal studies of the combination to treat non-small lung cancer (…

    Published on 1/16/2017
  • Innate Pharma, Bristol-Myers deal

    Innate received a $15 million milestone payment from Bristol-Myers under a 2011 deal granting BMS exclusive, worldwide rights to lirilumab, a human mAb against killer cell immunoglobulin-like receptors (KIR). Innate …

    Published on 1/16/2017
  • InVivo, PixarBio deal

    PixarBio proposed to acquire InVivo for $100 million in stock. The combined company would be renamed Reynolds Therapeutics Corp. and focus on pain, spinal cord injury, adaptive technologies, epilepsy and Parkinson's …

    Published on 1/16/2017
  • Ionis, Novartis deal

    Ionis and its Akcea Therapeutics Inc. subsidiary granted Novartis exclusive, worldwide options to develop and commercialize AKCEA-APO(a)-LRx (IONIS-APO(a)-LRx) and AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx), which are …

    Published on 1/16/2017
  • Kite, Daiichi Sankyo deal

    Kite granted Daiichi Sankyo rights in Japan to develop and commercialize chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (KTE-C19). Kite will receive $50 million up front and is eligible for up to…

    Published on 1/16/2017
  • Kite, Fosun deal

    Kite and Fosun formed the JV Fosun Pharma Kite Biotechnology Co. Ltd. (Shanghai, China) to develop Kite's lead chimeric antigen receptor (CAR) T cell immunotherapy candidate, axicabtagene ciloleucel (KTE-C19), in China.…

    Published on 1/16/2017
  • Lilly, Merck deal

    Lilly and Merck partnered to conduct a Phase I trial of Lilly's soft tissue sarcoma (STS) drug Lartruvo olaratumab with Merck's cancer drug Keytruda pembrolizumab in patients with previously treated advanced or …

    Published on 1/16/2017
  • Lysosomal, Allergan deal

    Allergan purchased from Lysosomal an exclusive option to acquire the company following completion of a Phase Ib trial of LTI-291. The preclinical candidate is designed to simulate activity of glucocerebrosidase (GBA; …

    Published on 1/16/2017
  • Maverick Therapeutics, Takeda deal

    Maverick and Takeda partnered to develop the biotechs T cell engagement platform to improve T cell redirection therapies. Takeda provided $125 million in funding split across an upfront option payment, R&D payments …

    Published on 1/16/2017
  • Merrimack, Ipsen deal

    Ipsen will acquire the commercial business of Merrimack, including U.S. rights to Onivyde irinotecan and Merrimacks generic doxorubicin product. The companies expect the deal to close this quarter. Merrimack markets …

    Published on 1/16/2017

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993